Primary non hodgkin's lymphoma of lacrimal sac presented as recurrent acute dacryocystitis: A case report

Primary non Hodgkin's lymphoma of the lacrimal sac is uncommon but potentially delay in diagnosis as it may mimic the presentation of primary post saccal nasolacrimal duct obstruction. In this article, we reported a case of primary non Hodgkin's lymphoma of the lacrimal sac presented with recurrent acute dacryocystitis in a young lady. A 28 years old Malay lady had history of persistent epiphora on left eye for 4 years. Prior to presentation to our clinic, it was preceded by progressive recurrent painful medial canthal swelling for 6 months duration. Clinical diagnosis of post saccal naso lacrimal duct obstruction was made and otorhinolaryngology assessment revealed intranasal mass. Endoscopic excision was done showed diffuse large B cell lymphoma on histology. The patient was started on 6 cycles of chemotherapy which subsequently result in no recurrence of the tumour post chemotherapy. Any case of post saccal nasolacrimal duct obstruction should be investigated thoroughly as it may become as a presentation of other sinister pathology.

P53 Gene Mutations in Non-Hodgkin's Lymphoma

Summary: To understand P53 gene change of non Hodgkin's lymphoma (NHL) and human malignant lymphoma cell lines, the exons 5 7 of 29 patients with NHL and 9 kinds of human malignant lymphoma cell lines were studied by silver staining PCR SSCP technique. Three cases of P53 gene point mutation was found in 29 cases of NHL. Mutation developed in exon 5 in 2 cases, and in exon 6 in 1 case. They were all diffuse lymphoma. In mutation cases, B cell lymphoma accounted for 2 cases and the other one was T cell lymphoma. There was no P53 gene mutation in low grade follicular lymphoma. Seven strains out of 9 kinds of lymphoma cell lines had P53 gene point mutation. One strain had the mutation in exon 5; 5 strains in exon 6 and 1 strain in exons 5, 6, 7. There was a high mutation rate in lymphoma cell lines and low mutation rate in NHL patients. P53 gene plays an important role in lymphoma cell line establishment, cell regeneration and disease evolution.

肠道B细胞淋巴瘤Epstein-Barr病毒感染与癌基因

目的 :研究肠道非霍奇金淋巴瘤B细胞型的Epstein Barr(EB)病毒感染、p5 3、p2 1ras基因表达及其相关性。方法 :应用单克隆抗体、免疫组化方法对瘤细胞进行免疫表型研究 ,CD2 0、CD45RA、CD79a鉴定瘤细胞的B细胞分化 ,CD45RO、CD3除外瘤细胞T细胞分化。同时用免疫组化方法 ,检测瘤细胞 p5 3基因表达、p2 1ras基因表达。EB病毒寡核苷酸探针 (EBER)原位杂交 ,观察瘤细胞EB病毒感染情况。结果 :34例肠道B细胞淋巴瘤好发部位为回肠和结肠 ,以单发瘤结节多见 ,常伴有表面溃疡形成。 34例中 ,弥漫性大B细胞淋巴瘤 9例 (2 6 .5 % ) ,19例为惰性的边缘区B细胞淋巴瘤黏膜相关淋巴组织型 (MZL MALT型 ) (5 5 .9% ) ,6例为MZL MALT型伴高度恶性转化(17.6 % )。EBV EBER原位杂交检测 ,全部病例为阴性。p5 3蛋白表达共有 2 3例 ,占全部病例的 6 7.6 % (其中高度恶性占 47.8% ) ;16例有 p2 1ras的表达 ,为 47.1% (其中高度恶性占 43.8% )。有 15例同时检出 p5 3蛋白和p2 1ras的表达 ,占病例数的 44 .1%。结论 :34例肠道B细胞淋巴瘤以惰性为多见 ,但恶性转化明显。EBV的研究提示肠道B细胞淋巴瘤有别于T细胞淋巴瘤 ,与EBV感染无关。p5 3蛋白的表达高于 p2 1ras,p5 3和 p2 1ras的共同表达检出率较高 ,提示癌基因 p5

大肠原发性恶性淋巴瘤的临床特点及治疗

目的：探讨大肠原发性恶性淋巴瘤的临床与病理特点。方法：对１４例大肠原发性恶性淋巴瘤患者的临床资料作回顾性分析，按１９８５年我国成都ＮＨＬ分类和ＷＨＯ新分类进行组织学分类。结果：１４例均经手术治疗无并发症。随访５年生存率为４２．８％，其中低度恶性淋巴瘤Ｂ细胞性３例（２１．４％），中度恶性淋巴瘤Ｂ细胞性、高度恶性淋巴瘤Ｔ细胞性及分类不明的淋巴瘤各１例。